Literature DB >> 19027144

Effects of naturally occurring mutations in CUB-1 domain on synthesis, stability, and activity of ADAMTS-13.

Zhou Zhou1, Hua Jing, Zhenyin Tao, Huiwan Choi, Khatira Aboulfatova, Joel Moake, Renhao Li, Jing-Fei Dong.   

Abstract

INTRODUCTION: Upon stimulation, endothelial cells release von Willebrand factor (VWF) in the unusually large (UL) and hyperactive forms that are rapidly cleaved by ADAMTS-13. Mutations in the ADAMTS13 gene result in ULVWF-mediated thrombosis found in patients with familial thrombotic thrombocytopenia purpura (TTP). ADAMTS-13 fits in the consensus of the ADAMTS family metalloproteases, but also contains two unique C- terminal CUB domains. Studying mutations in CUB domains could provide insights into the functional role of these domains.
METHODS: Three naturally occurring mutations (C1213Y, W1245del and K1256FS) in the CUB-1 domain found in patients with TTP were expressed in Hela cells. The secretion, stability and VWF-cleaving activity of the mutants under static and flow conditions were examined.
RESULTS: The mutations impaired secretion of ADAMTS-13 to apical surface, but not to extracellular matrix of transfected Hela cells. C1213Y and K1256FS also accelerated, whereas W1245del delayed, extracellular degradation of the mutants. The mutations also resulted in a moderate decrease in cleaving plasma VWF under static conditions. However, the mutated ADAMTS-13 bound to VWF substrate similarly as the wild-type metalloprotease and remained active in cleaving (UL)VWF under flow conditions.
CONCLUSIONS: The CUB-1 domain is critical for ADAMTS-13 secretion and stability upon secretion. ADAMTS-13 deficiency found in TTP patients could be resulted from reduced ADAMTS-13 secretion and, in the case of C1213Y and K1256FS accelerated degradation. W1245del is highly resistant to degradation and active in cleaving VWF.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19027144      PMCID: PMC5649364          DOI: 10.1016/j.thromres.2008.09.007

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  25 in total

1.  Inhibitory autoantibodies against ADAMTS-13 in patients with thrombotic thrombocytopenic purpura bind ADAMTS-13 protease and may accelerate its clearance in vivo.

Authors:  S G Shelat; P Smith; J Ai; X L Zheng
Journal:  J Thromb Haemost       Date:  2006-08       Impact factor: 5.824

2.  Novel ADAMTS-13 mutations in an adult with delayed onset thrombotic thrombocytopenic purpura.

Authors:  Z Tao; K Anthony; Y Peng; H Choi; L Nolasco; L Rice; J L Moake; J-F Dong
Journal:  J Thromb Haemost       Date:  2006-06-22       Impact factor: 5.824

3.  Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.

Authors:  X Zheng; D Chung; T K Takayama; E M Majerus; J E Sadler; K Fujikawa
Journal:  J Biol Chem       Date:  2001-09-13       Impact factor: 5.157

4.  ADAMTS13 is expressed in hepatic stellate cells.

Authors:  Wenhua Zhou; Mari Inada; Tai-Ping Lee; Daniel Benten; Sergey Lyubsky; Eric E Bouhassira; Sanjeev Gupta; Han-Mou Tsai
Journal:  Lab Invest       Date:  2005-06       Impact factor: 5.662

5.  Binding of ADAMTS13 to von Willebrand factor.

Authors:  Elaine M Majerus; Patricia J Anderson; J Evan Sadler
Journal:  J Biol Chem       Date:  2005-04-11       Impact factor: 5.157

6.  Localization of ADAMTS13 to the stellate cells of human liver.

Authors:  Masahito Uemura; Kouko Tatsumi; Masanori Matsumoto; Masao Fujimoto; Tomomi Matsuyama; Masatoshi Ishikawa; Taka-Aki Iwamoto; Toshio Mori; Akio Wanaka; Hiroshi Fukui; Yoshihiro Fujimura
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

7.  Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura.

Authors:  G G Levy; W C Nichols; E C Lian; T Foroud; J N McClintick; B M McGee; A Y Yang; D R Siemieniak; K R Stark; R Gruppo; R Sarode; S B Shurin; V Chandrasekaran; S P Stabler; H Sabio; E E Bouhassira; J D Upshaw; D Ginsburg; H M Tsai
Journal:  Nature       Date:  2001-10-04       Impact factor: 49.962

8.  Cleavage of the ADAMTS13 propeptide is not required for protease activity.

Authors:  Elaine M Majerus; Xinglong Zheng; Elodee A Tuley; J Evan Sadler
Journal:  J Biol Chem       Date:  2003-09-15       Impact factor: 5.157

9.  Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).

Authors:  Christoph Licht; Ludwig Stapenhorst; Thorsten Simon; Ulrich Budde; Reinhard Schneppenheim; Bernd Hoppe
Journal:  Kidney Int       Date:  2004-09       Impact factor: 10.612

10.  The cooperative activity between the carboxyl-terminal TSP1 repeats and the CUB domains of ADAMTS13 is crucial for recognition of von Willebrand factor under flow.

Authors:  Ping Zhang; Weilan Pan; Ann H Rux; Bruce S Sachais; X Long Zheng
Journal:  Blood       Date:  2007-05-31       Impact factor: 22.113

View more
  3 in total

1.  Dynamic regulation of platelet-derived growth factor D (PDGF-D) activity and extracellular spatial distribution by matriptase-mediated proteolysis.

Authors:  Wei Huang; Hyeong-Reh Choi Kim
Journal:  J Biol Chem       Date:  2015-02-12       Impact factor: 5.157

Review 2.  Role of matriptase-2 (TMPRSS6) in iron metabolism.

Authors:  Pauline Lee
Journal:  Acta Haematol       Date:  2009-11-10       Impact factor: 2.195

3.  Novel mutations in ADAMTS13 CUB domains cause abnormal pre-mRNA splicing and defective secretion of ADAMTS13.

Authors:  Yizhi Jiang; Dongping Huang; Yuji Kondo; Miao Jiang; Zhenni Ma; Lu Zhou; Jian Su; Xia Bai; Changgeng Ruan; Zhaoyue Wang; Lijun Xia
Journal:  J Cell Mol Med       Date:  2020-02-19       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.